Reported about 14 hours ago
West Pharmaceutical Services is set to announce its Q2 2025 earnings on July 24, with analysts predicting a profit of $1.51 per share, slightly down from $1.52 a year prior. The company has experienced significant stock decline, at 30.7% compared to the S&P 500’s 13.4% increase over the past 52 weeks. Despite challenges, analysts maintain a positive outlook, with a consensus ‘Strong Buy’ rating reflecting a potential upside of 25.8%. The company's adjusted EPS projection for the year is $6.28, down from $6.75 in fiscal 2024.
Source: YAHOO